Finney Kevin 4

What Happened

• Kevin Finney, a director of Vaxart, received awards totaling 118,100 shares on July 16, 2026. The filing shows 39,400 shares granted as restricted stock units (RSUs) and 78,700 shares as a derivative award (an option-type award), each reported at $0.00 (no cash paid). The reported total value at grant was $0.

Key Details

• Transaction date: July 16, 2026; Filing date: July 20, 2026 (reported 4 days after the transactions).
• Grants: 39,400 RSUs (F1) and 78,700 derivative shares/options (F2); combined = 118,100 shares.
• Price: $0.00 per share (award/compensation, not a market purchase).
• Vesting: Both awards vest on the earlier of the date immediately prior to the 2027 annual meeting of stockholders and July 16, 2027 (first anniversary of the grant) — per footnotes F1 and F2.
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Filing timeliness: Filed July 20 for a July 16 transaction; this is later than the typical two-business-day Form 4 window—check the filing for any tardiness flag.

Context

• These are compensation awards (RSUs/options) that vest in the future, not open-market purchases or sales. Derivative award means the right to receive shares subject to vesting conditions; it does not represent immediate sale or cash proceeds. Such grants are routine for executive/director compensation and do not by themselves indicate buying or selling sentiment.